These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2504781)
21. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. Lee JH; Dunner DL Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265 [TBL] [Abstract][Full Text] [Related]
22. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. Fabre LF; Putman HP J Clin Psychiatry; 1987 Oct; 48(10):406-8. PubMed ID: 3312176 [TBL] [Abstract][Full Text] [Related]
23. A prospective long-term follow-up study of alexithymia in obsessive-compulsive disorder. Rufer M; Ziegler A; Alsleben H; Fricke S; Ortmann J; Brückner E; Hand I; Peter H Compr Psychiatry; 2006; 47(5):394-8. PubMed ID: 16905403 [TBL] [Abstract][Full Text] [Related]
27. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Cook EH; Rowlett R; Jaselskis C; Leventhal BL J Am Acad Child Adolesc Psychiatry; 1992 Jul; 31(4):739-45. PubMed ID: 1644739 [TBL] [Abstract][Full Text] [Related]
28. Open trial of fluoxetine in obsessive-compulsive disorder. Jenike MA; Buttolph L; Baer L; Ricciardi J; Holland A Am J Psychiatry; 1989 Jul; 146(7):909-11. PubMed ID: 2787123 [TBL] [Abstract][Full Text] [Related]
29. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253 [TBL] [Abstract][Full Text] [Related]
30. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. King RA; Riddle MA; Chappell PB; Hardin MT; Anderson GM; Lombroso P; Scahill L J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):179-86. PubMed ID: 2016219 [TBL] [Abstract][Full Text] [Related]
31. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519 [TBL] [Abstract][Full Text] [Related]
32. Tricyclic antidepressants in obsessive-compulsive disorder. Antiobsessional or antidepressant agents? Mavissakalian M; Michelson L J Nerv Ment Dis; 1983 May; 171(5):301-6. PubMed ID: 6343556 [TBL] [Abstract][Full Text] [Related]
33. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Markovitz PJ; Stagno SJ; Calabrese JR Am J Psychiatry; 1990 Jun; 147(6):798-800. PubMed ID: 2188516 [TBL] [Abstract][Full Text] [Related]
34. Buspirone in obsessional compulsive disorder. A prospective case study. Farid BT; Bulto M Pharmacopsychiatry; 1994 Sep; 27(5):207-9. PubMed ID: 7838892 [TBL] [Abstract][Full Text] [Related]
35. Fluoxetine for obsessive fear of loss of control of malodorous flatulence. Fishbain DA; Goldberg M Psychosomatics; 1991; 32(1):105-7. PubMed ID: 2003129 [No Abstract] [Full Text] [Related]
37. [Long term treatment of schizophrenia with penfluridol]. Haring C Med Welt; 1977 Apr; 28(13):639-42. PubMed ID: 404499 [No Abstract] [Full Text] [Related]
38. [Pharmacotoxic psychosis and extrapyramidal motor syndrome. A case of acute adverse effect of fluoxetine and flupenthixol]. Pach J Nervenarzt; 1992 Sep; 63(9):575-6. PubMed ID: 1407229 [No Abstract] [Full Text] [Related]
39. An open trial of buspirone in obsessive-compulsive disorder. Jenike MA; Baer L Am J Psychiatry; 1988 Oct; 145(10):1285-6. PubMed ID: 3048120 [TBL] [Abstract][Full Text] [Related]